Align Technology (ALGN)
(Delayed Data from NSDQ)
$271.70 USD
-8.69 (-3.10%)
Updated May 10, 2024 04:00 PM ET
After-Market: $271.68 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$271.70 USD
-8.69 (-3.10%)
Updated May 10, 2024 04:00 PM ET
After-Market: $271.68 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition
by Zacks Equity Research
Neogen (NEOG) faces intense competition from companies ranging from small businesses to divisions of large multinational companies.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall first-quarter performance.
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
by Zacks Equity Research
PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
by Zacks Equity Research
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.
QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.
OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.
McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.
Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up
by Zacks Equity Research
Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.
Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
by Zacks Equity Research
Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.
GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS
by Zacks Equity Research
GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.
Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its first-quarter performance.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline
by Zacks Equity Research
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
by Zacks Equity Research
GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.